NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial ResultsGlobeNewsWire • 04/24/24
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024GlobeNewsWire • 04/17/24
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-IrradiationGlobeNewsWire • 04/02/24
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer StudyGlobeNewsWire • 01/29/24
NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023GlobeNewsWire • 11/09/23
NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6MGlobeNewsWire • 11/06/23
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55MGlobeNewsWire • 11/02/23
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash CovenantGlobeNewsWire • 11/01/23
NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023GlobeNewsWire • 10/23/23
Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 MonthsGlobeNewsWire • 10/04/23
NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation OncologyGlobeNewsWire • 09/29/23
NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic CancerGlobeNewsWire • 09/28/23
NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023GlobeNewsWire • 09/26/23
Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023GlobeNewsWire • 09/19/23
NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical OfficerGlobeNewsWire • 09/05/23
NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 08/31/23
NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3GlobeNewsWire • 08/15/23